NextCure Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
/ 
Others were interested in
Frequently asked questions
To buy NextCure Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for NextCure Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for NextCure Inc. is NXTC:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
NextCure Inc. has its primary listing on NASDAQ. You can trade NextCure Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, NextCure Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include NextCure Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like NextCure Inc..